UroGen Pharma (URGN) Misses Q3 EPS by 23c

UroGen Pharma (NASDAQ: URGN) reported Q3 EPS of ($1.28), $0.23 worse than the analyst estimate of ($1.05).

“We are pleased by the FDA’s support for UGN-101 and recognition of the potential clinical benefit that UGN-101 presents for LG UTUC as a potentially organ-sparing, non-invasive therapy for this disease,” said Ron Bentsur, Chief Executive Officer of UroGen. “We are excited about the progress that we continue to make across our clinical pipeline and look forward to collaborating with the FDA to bring this potentially transformative therapy to patients with LG UTUC.”

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c